Cover Image
市場調查報告書

全球帕金森氏症市場調查

Global Parkinson's Disease Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 357628
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
全球帕金森氏症市場調查 Global Parkinson's Disease Market Report: 2016 Edition
出版日期: 2016年05月04日 內容資訊: 英文 51 Pages
簡介

本報告提供全球帕金森氏症治療藥市場相關資料,尤其是美國、EU及日本關註分析,主要的市場趨勢,推動成長因素與業界所面臨的課題,市場動態,競爭情形,及主要企業簡介等系統性資訊。

第1章 市場概要

第2章 全球市場

  • 全球帕金森氏症治療藥市場:以金額為準
    • 全球帕金森氏症治療藥市場:各地區
    • 全球帕金森氏症治療藥市場:各類藥物
    • 全球帕金森氏症患者人口:各重症度
    • 全球帕金森氏症患者人口:各地區

第3章 地區市場

  • 美國
    • 美國的帕金森氏症市場:以金額、數量為準
    • 美國的帕金森氏症市場規模 (以金額為準) :各分類
    • 美國的帕金森氏症市場規模 (以數量為準) :各分類
    • 美國的帕金森氏症市場:各類藥物
    • 美國的帕金森氏症首發藥市場
    • 美國的帕金森氏症後出發藥市場
  • EU
    • EU的帕金森氏症患者數、診斷
    • EU的帕金森氏症治療藥市場規模 (以金額為準)
  • 日本
    • 日本的帕金森氏症治療藥市場規模 (以金額為準)

第4章 市場動態

  • 成長推動因素
    • 毒物暴露層級的上升
    • 平均壽命的上升
    • 男性人口的增加
    • 老年人口的增加
    • 全球醫療費
    • 殺蟲劑的消費
  • 趨勢
    • 後期階段的帕金森氏症藥物研發
    • 幹細胞療法是有前途的治療
    • 帕金森氏症開發中的生技藥品
  • 課題
    • 仿製藥的侵蝕
    • 黑色素瘤風險高與相關的帕金森氏症治療
    • 目前治療的限制

第5章 競爭情形

  • 美國的帕金森氏症首發藥市場:各企業
  • 美國的帕金森氏症後出發藥市場:各企業

第6章 企業簡介

  • Biotie Therapies Corp.
    • 產業概要
    • 財務概要
    • 產業策略
  • Adamas Pharmaceuticals Inc.
  • Lundbeck
  • Novartis

第7章 市場展望

  • 全球市場的預測
  • 預測手法

圖表

目錄

Parkinson's Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson's primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

The current treatment market for Parkinson's disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson's disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson's along with possibility of developing “Stem Cell” as a treatment therapy.

The Parkinson's disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson's disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

The report, “Global Parkinson's disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Fundamental Features
  • 1.3. Types of Parkinson's Disease
  • 1.4. Risk Factors
  • 1.5. Treatment Options

2. Global Market

  • 2.1. Global Parkinson's Disease Drug Market by Value
    • 2.1.1. Global Parkinson's Disease Drug Market by Region
    • 2.1.2. Global Parkinson's Disease Market by Drug Class
    • 2.1.3. Global Parkinson's Disease Patient Population by Severity
    • 2.1.4. Global Parkinson's Disease Patient Population by Region

3. Regional Markets

  • 3.1. The U.S.
    • 3.1.1. The U.S. Parkinson's Disease Market by Value & Volume
    • 3.1.2. The U.S. Parkinson's Disease Market Value by Category
    • 3.1.3. The U.S. Parkinson's Disease Market Volume by Category
    • 3.1.4. The U.S. Parkinson's Disease Market by Drug Class
    • 3.1.5. The U.S. Parkinson's Disease Branded Drugs Market
    • 3.1.6. The U.S. Parkinson's Disease Generic Drugs Market
  • 3.2. The European Union
    • 3.2.1. The E.U. Parkinson's Patient Prevalence & Diagnosis
    • 3.2.2. The European Parkinson's Disease Drug Market by Value
  • 3.3. Japan
    • 3.3.1. Japan's Parkinson's Disease Drug Market by Value

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Rising Level of Toxin Exposure
    • 4.1.2. Rising Life Expectancy
    • 4.1.3. Rising Male Population
    • 4.1.4. Increasing Ageing Population
    • 4.1.5. Global Healthcare Expenditure
    • 4.1.6. Pesticides Consumption
  • 4.2. Trends
    • 4.2.1. Late-Stage Drug Development for Parkinson's Disease
    • 4.2.2. Stem-Cell Therapy as Potential Treatment
    • 4.2.3. Biologics under Development for Parkinson's Disease
  • 4.3. Challenges
    • 4.3.1. Generic Erosion
    • 4.3.2. Parkinson's Treatment associated with Higher Risk of Melanoma
    • 4.3.3. Current Treatment Limitation

5. Competitive Landscape

  • 5.1. The U.S. Parkinson's Disease Branded Drug Market by Company
  • 5.2. The U.S. Parkinson's Disease Generic Drug Market by Company

6. Company Profiles

  • 6.1. Biotie Therapies Corp.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Adamas Pharmaceuticals Inc.
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Lundbeck
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Novartis
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

7. Market Outlook

  • 7.1. Global Market Forecast
  • 7.2. Forecast Methodology
    • 7.2.1. Dependent and Independent Variables
    • 7.2.2. Correlation Analysis

List of Charts

  • Global Parkinson's Disease Drug Market by Value (2010-2015E)
  • Global Parkinson's Disease Drug Market by Region (2014)
  • Global Parkinson's Disease Market by Drug Class (2015E)
  • Global Parkinson's Disease Patient Population by Severity (2015E)
  • Global Parkinson's Disease Patient Population by Region (2015E)
  • The U.S. Parkinson's Disease Market by Value & Volume (2013-2020E)
  • The U.S. Parkinson's Disease Market Value by Category (2013-2017E)
  • The U.S. Parkinson's Disease Market Volume by Category (2015)
  • The U.S. Parkinson's Disease Market by Drug Class (2015)
  • The U.S. Parkinson's Branded Drugs Market by Value & Volume (2013-2020E)
  • The U.S. Parkinson's Generic Drugs Market by Value & Volume (2013-2020E)
  • The E.U. Parkinson's Disease Prevalence and Diagnosis (2013-2018E)
  • The European Parkinson's Disease Drug Market by Value (2014/2015)
  • Japan's Parkinson's Disease Drug Market by Value (2014/2015)
  • Global Lead Production (2000-2014)
  • Global Life Expectancy at Birth (2008-2014E)
  • Global Male Population (2009-2014)
  • Global Ageing Population above 65 Years (2009-2014)
  • Global Healthcare Expenditure (2009-2014)
  • The U.S Parkinson's Disease Branded Market by Drug (2015)
  • The U.S. Parkinson's Disease Generic Market by Drug (2015)
  • Portfolio of Innovative CNS Medicines
  • Biotie Therapies Corp Revenue & Net Income/Loss (2011-2015)
  • Biotie's Research and Development Expenditure (2011-2015)
  • Adamas Pharmaceuticals Revenue and Net Income/Loss (2012-2015)
  • Adamas Pharmaceutical's R&D Expenditure (2012-2015)
  • Lundbeck's Revenue Share by Product (2014)
  • Lundbeck's Revenue Share by Region (2014)
  • Lundbeck's Revenue and Annual Growth (2012-2017E)
  • Novartis Revenue by Business Segments (2015)
  • Novartis Revenue and Net Income (2011-2015)
  • Global Parkinson's Disease Market Forecast (2013-2017F)

List of Tables

  • Currently Leading Treatment Drugs for Parkinson's Disease
  • Selected Late-Stage Drugs for Parkinson's
  • Selected Late-Stage Drugs for Parkinson's Disease
  • Biologics under Development for Parkinson's Disease
  • Adamas Pharmaceuticals Therapeutic Portfolio
  • Lundbeck's Product Pipeline
  • Dependent and Independent Variable
  • Correlation Matrix
  • Model Summary - Coefficient of Determination
  • Regression Coefficients Output
Back to Top